theMednetRegister
JAMA oncology 2025 Apr 03
Management of EGFR-Variant and ALK-Positive Non-Small Cell Lung Cancer Brain Metastasis.   

Related Questions

Is it acceptable to treat patients with limited, asymptomatic brain metastases and EGFR-mutant NSCLC with upfront TKI?
Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?
Copyright © 2025 theMednet
All Rights Reserved.